BETHESDA, MD / ACCESSWIRE / November 23, 2020 / HF Enterprises Inc. (NASDAQ:HFEN)(the "Company"), a diversified holding company principally engaged through its subsidiaries in property development, digital transformation technology and biohealth activities, today announced the pricing of its initial public offering of 2,160,000 shares of its common stock at a public offering price of $7.00 per share for gross proceeds of $15,120,000 before deducting offering expenses. In addition, the Company has granted Aegis Capital Corp. a 60-day option to purchase up to 15% of additional shares of common stock at the public offering price to cover over-allotments, if any. The shares are expected to begin trading on The Nasdaq Capital Market on November 24, 2020, under the symbol "HFEN."

Aegis Capital Corp. is acting as lead bookrunning manager.

WestPark Capital, Inc. is acting as co-manager.

A registration statement relating to the shares of common stock being sold in this offering was declared effective by the Securities and Exchange Commission (the "SEC") on November 12, 2020. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, on the SEC's website, www.sec.gov, or by contacting Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th Floor, New York, NY 10019, by email at syndicate@aegiscap.com, or by telephone at (212) 813-1010.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About HF Enterprises Inc.

HF Enterprises Inc. is a diversified holding company principally engaged through its subsidiaries in property development, digital transformation technology and biohealth activities with operations in the United States, Singapore, Hong Kong, Australia and South Korea. The Company manages its three principal businesses primarily through its subsidiary, Alset International Limited (formerly known as "Singapore eDevelopment Limited"), a public company traded on the Singapore Stock Exchange. Through this subsidiary (and indirectly, through other public and private U.S. and Asian subsidiaries), the Company is actively developing two significant real estate projects near Houston, Texas and in Frederick, Maryland in the property development segment. The Company has designed applications for enterprise messaging and e-commerce software platforms in the United States and Asia in the digital transformation technology business unit. The Company's recent foray into the biohealth segment primarily includes research to treat neurological and immune-related diseases, nutritional chemistry to create a natural sugar alternative, research regarding innovative products to slow the spread of disease, and certain natural foods and supplements.

Investor Contact:

Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
Dave@redchip.com

Forward-Looking Statement Disclaimer

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, including the Company's expectations regarding the proposed offering of the Company's shares of common stock, including as to the consummation of the offering described above and the size of the offering are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the SEC. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: HF Enterprises Inc.

ReleaseID: 618131

Industry Veteran Brings Deep R&D and Clinical Development Experience to Tarus

NEW YORK, NY / ACCESSWIRE / November 24, 2020 / Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy and select non-oncology indications, today announced that Dr. Brian Schwartz, M.D. has joined the company as Acting Chief Medical Officer and Head of the Scientific Advisory Board (SAB).

Dr. Schwartz was Chief Medical Officer at ArQule from 2008, and also Head of Research & Development from 2013, until the company's acquisition by Merck in 2020 for $2.7 billion. Dr. Schwartz has extensive experience in the pharmaceutical and biotechnology industries. Prior to joining ArQule, he was Chief Medical Officer and Senior Vice President, Clinical and Regulatory Affairs, at Ziopharm Oncology where he built and led the clinical, regulatory, and quality assurance departments with responsibilities for the development of new cancer drugs. Prior to Ziopharm, Dr. Schwartz held a number of leadership positions at Bayer Healthcare. At Bayer, Dr. Schwartz was a key physician responsible for the global clinical development of sorafenib (Nexavar®) and led the clinical team through a successful Phase 3 trial in renal cell cancer, leading to U.S. Food and Drug Administration (FDA) approval. He has extensive regulatory experience working with the FDA's Oncology Division, the European Medicines Agency (EMA), and numerous other health authorities. Dr. Schwartz has been involved in multiple clinical and regulatory activities, including Phase 4 studies and interactions with the National Cancer Institute and other oncology cooperative groups. Dr. Schwartz received his medical degree from the University of Pretoria, South Africa, practiced medicine, and worked at the University of Toronto prior to his career in industry. Dr. Schwartz serves on the Boards of Mereo Pharma Group Plc, LifeSci Acquisition Corp and Enlivex Therapeutics Ltd. He is also an advisor to the California Institute of Regenerative Medicine and Pontifax Venture Capital.

"With our IND submissions for multiple programs and indications expected in the near term, Tarus is positioned to rapidly expand its focus on clinical development," said Sushant Kumar, Ph.D., Chief Executive Officer of Tarus Therapeutics. "We are delighted to welcome Dr. Schwartz to Tarus' s leadership team. Dr. Schwartz's deep insight and expertise in clinical development of oncology drugs will be invaluable as we execute our clinical strategy," added Dr. Kumar.

"I am excited to join the Tarus team and look forward to overseeing its research programs and leading the clinical development of multiple programs focused on adenosine receptor antagonism, a promising new area in immuno-oncology," said Dr. Schwartz.

About Tarus Therapeutics Inc.

Tarus is developing small molecule inhibitors of A2AR, A2BR, and Dual A2AR/A2BR inhibitors for cancer immunotherapy and select non-oncology indications. The Company has the most comprehensive portfolio of adenosine receptor antagonists in development, with both first-in-class and best-in-class programs. More information can be found at www.tarustx.com.

Contact:

Tarus Therapeutics, Inc.
Sushant Kumar, PhD
President & CEO
info@tarustx.com

SOURCE: Tarus Therapeutics

ReleaseID: 618007

GENEVA, SWITZERLAND and RADNOR, PA / ACCESSWIRE / November 24, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company") and NeuroRx, Inc., announced that more than 175 patients with Critical COVID-19 and Respiratory Failure who also have a severe comorbidity have now been entered into an Expanded Access Protocol (EAP) with RLF-100(TM) in the United States.

All patients had severe comorbidities (such as organ transplant, recent heart attack, and cancer) that rendered them ineligible for the ongoing randomized, controlled phase 2b/3 trial being conducted to ascertain safety and efficacy of RLF-100(TM), and all patients were deteriorating despite treatment with approved therapies for COVID-19 (see www.clinicaltrials.gov NCT 04311697). Of the 90 patients who have so far reached 28 days of follow-up, 72% survived to day 28.

As previously reported by Youssef and coworkers (http://dx.doi.org/10.2139/ssrn.3665228), at Houston Methodist Hospital, 21 patients treated with RLF-100(TM) under the EAP were compared to 24 control patients treated in the same setting. Only 17% of the control patients, all treated with best available intensive care unit (ICU) Standard of Care, survived to day 28. The survival rate with RLF-100(TM) reported today is comparable to that seen among the open-label patients treated with RLF-100(TM) by Youssef et al. Despite advancements in treating COVID-19, survival for the patients at highest risk due to severe comorbidities has remained dismal in the absence of an effective therapy.

Notably, in the EAP, no drug-related Serious Adverse Events have been reported to date among these patients nor the 160 patients randomized to RLF-100(TM) vs. placebo in the U.S. phase 2b/3 clinical trial currently underway. Thus, from a risk/benefit perspective, while the benefit of RLF-100(TM) has not yet been proven in a randomized prospective trial, no serious risk has been identified so far.

Currently, 25 U.S. hospitals have enrolled patients in the EAP, nearly all of which are community hospitals, suggesting that RLF-100(TM) can demonstrate effectiveness in the hands of front-line physicians who deliver the majority of care to patients with Critical COVID-19. Physicians enrolling patients in the EAP have routinely reported that initial patients at their sites have frequently been in the ICU for several weeks without recovery prior to treatment with RLF-100(TM). As patients are treated earlier in the course of their ICU stay, there is an emerging clinical impression that RLF-100(TM) has an even greater impact on recovery.

"We are reassured that emerging real-world data on the use of RLF-100(TM) in improving survival in patients with Critical COVID-19 are comparable to results seen in the hands of major academic teaching centers. We hope that these findings are viewed as encouraging at a time when many Americans, including the doctors, nurses, and other front-line caregivers who are the heart of our initiative, are celebrating the Thanksgiving holiday at a distance from their loved ones. We look forward to completing enrollment and reporting the results of our pivotal U.S. clinical trial," said Prof. Jonathan C. Javitt, MD, MPH, CEO and founder of NeuroRx, Inc.

ABOUT VIP IN LUNG INJURY
Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970. Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, 70% of the VIP in the body is bound to a rare cell in the lung, the alveolar type 2 cell, that is critical to transmission of oxygen to the body. VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.

COVID-19-related death is primarily caused by respiratory failure. Before this acute phase, however, there is evidence of early viral infection of the alveolar type 2 cells. These cells are known to have angiotensin converting enzyme 2 (ACE2) receptors at high levels, which serve as the route of entry for the SARS-CoV-2 into the cells. Coronaviruses are shown to replicate in alveolar type 2 cells but not in the more numerous type 1 cells. These same type 2 alveolar cells have high concentrations of VIP receptors on their cell surfaces giving rise to the hypothesis that VIP could specifically protect these cells from injury.

Injury to the type 2 alveolar cells is an increasingly plausible mechanism of COVID-19 disease progression (Mason 2020). These specialized cells replenish the more common type 1 cells that line the lungs. More importantly, type 2 cells manufacture surfactant that coats the lung and are essential for oxygen exchange. Other than RLF-100(TM), no currently proposed treatments for COVID-19 specifically target these vulnerable type 2 cells.

ABOUT RLF-100(TM)
RLF-100(TM) (Aviptadil) is a formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Sami Said's original work at Stony Brook University, for which Stony Brook was awarded an FDA Orphan Drug Designation in 2001. VIP is known to be highly concentrated in the lungs, where it inhibits coronavirus replication, blocks the formation of inflammatory cytokines, prevents cell death, and upregulates the production of surfactant. FDA has now granted IND authorization for intravenous and inhaled delivery of RLF-100(TM) for the treatment of COVID-19 and awarded Fast Track designation. RLF-100(TM) is being investigated in two placebo-controlled US Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Since July 2020, more than 150 patients with Critical COVID-19 and Respiratory Failure have been treated with RLF-100(TM) under FDA-approved protocols. Information on the RLF-100(TM) Expanded Access program is at https://www.neurorxpharma.com/our-services/rlf-100.

ABOUT RELIEF THERAPEUTICS HOLDING AG
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Relief holds orphan drug designations from the U.S. FDA and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a patent issued in the U.S. and multiple other countries covering potential formulations of RLF-100(TM).

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on the OTCQB under the symbol RLFTF.

ABOUT NEURORX INC.
NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100(TM), NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer's Neuroscience and Pain Division. Its Board of Directors and Advisors includes Hon. Sherry Glied, former Assistant Secretary, U.S. Dept. of Health and Human Services; Mr. Chaim Hurvitz, former President of the Teva International Group, Lt. Gen. HR McMaster, the 23rd National Security Advisor, Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, Judge Abraham Sofaer, and Daniel Troy, former Chief Counsel, U.S. Food and Drug Administration.

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. The results reported herein may or may not be indicative of the results of future and larger clinical trials for RLF-100(TM) for the treatment of COVID-19. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

CORPORATE CONTACT
RELIEF THERAPEUTICS Holding AG
Raghuram (Ram) Selvaraju, Ph.D., MBA
Chairman of the Board
Mail: contact@relieftherapeutics.com
www.relieftherapeutics.com

NeuroRx, Inc.
Jonathan C. Javitt, M.D., MPH
Chairman and Chief Executive Officer
Mail: ceo@neurorxpharma.com

MEDIA CONTACT:
Relief (Europe)
MC Services AG
Anne Hennecke / Brittney Sojeva
Tel.: +49 (0) 211-529-252-14
Mail: relief@mc-services.eu

NeuroRx (United States)
David Schull
Russo Partners, LLC
Tel.: +1 (0) 858-717-2310
Mail: david.schull@russopartnersllc.com

INVESTOR RELATIONS
Relief (Europe)
MC Services AG
Anne Hennecke / Brittney Sojeva
Tel.: +49 (0) 211-529-252-14
Mail: relief@mc-services.eu

NeuroRx (United States)
Brian Korb
Solebury Trout
Tel.: +1 (0) 917-653-5122
Mail: bkorb@troutgroup.com

SOURCE: Relief Therapeutics Holdings AG via EQS Newswire

ReleaseID: 618165

Implements New Corporate Strategy to Focus on Precision Therapeutics for the Treatment of Cancer
Strengthens Pipeline by Acquiring a Proprietary Portfolio of Novel Adenosine Immuno-Modulator Compounds
Increased Cash Runway by Securing $500,000 of Gross Proceeds From an Existing Institutional Investor in October 2020

WESTLAKE VILLAGE, CA / ACCESSWIRE / November 24, 2020 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, today reported its financial results for the third quarter ended September 30, 2020.

Business Highlights

During the third quarter, the company continued to execute on implementing a new corporate strategy by strengthening its portfolio and securing additional capital to pursue long-term strategic objectives and create value for stakeholders.
In October 2020, we sold additional convertible debentures resulting in $500,000 from existing investors.
In October 2020, we announced that the company would strengthen its strategic collaboration with Ridgeway Therapeutics by reacquiring its novel immune-oncology precision targeting platform for the treatment of cancer through the cancellation of our prior licensing agreement.
Inspyr and Ridgeway will pursue the research and development of RT-AR001, a potential first-in-class adenosine receptor modulator. The novel delivery technology is differentiated by its microparticle formulation that allows for better tumor infiltration and enhanced outcomes when administered intra-tumorally and has demonstrated delayed tumor growth, reduced metastases and enhanced anti-tumor immune activities in pre-clinical studies.

The company is now in the process of commencing corporate operations including: pre-clinical research and development, manufacturing, regulatory and business development. The company is dedicated to continuing to execute its new corporate strategy and will provide timely updates to shareholders.

Financial Results for the Quarter Ended September 30, 2020
Cash Position and Liquidity: At September 30, 2020, cash was approximately $33,000 as compared to approximately $116,000 at June 30, 2020.

Operating Loss: Operating loss for the quarter ended September 30, 2020 and the comparable period in 2019 were both $137,000. For the nine-month period ended September 30, 2020, the operating loss was approximately $377,000 versus $499,000 for the nine months ended September 30, 2019. The decrease in operating loss for 2020 was primarily due to a decrease in professional fees.

INSPYR THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)

 
September 30,
 
 
December 31,
 

 
2020
 
 
2019
 

 
(Unaudited)
 
 
 
 

ASSETS

Current assets:

Cash

 
$
4
 
 
$
4
 

Restricted cash

 
 
29
 
 
 
19
 

Total current assets

 
 
33
 
 
 
23
 

Total assets

 
$
33
 
 
$
23
 

LIABILITIES AND STOCKHOLDERS' DEFICIT

Current liabilities:

Accounts payable

 
$
2,330
 
 
$
2,269
 

Accrued expenses

 
 
1,940
 
 
 
1,866
 

Convertible debentures

 
 
2,143
 
 
 
2,826
 

Derivative liability

 
 
833
 
 
 
1,785
 

Total current liabilities

 
 
7,246
 
 
 
8,746
 

Total liabilities

 
 
7,246
 
 
 
8,746
 

Commitments and contingencies (Note 7)

 
 
–
 
 
 
–
 

Stockholders' deficit:

Convertible preferred stock, undesignated, par value $.0001 per share; 29,986,846 shares authorized, no shares issued and outstanding, respectively

 
 
–
 
 
 
–
 

Convertible preferred stock Series A, par value $.0001 per share; 1,854 shares authorized, 134 shares issued and outstanding, respectively

 
 
–
 
 
 
–
 

Convertible preferred stock Series B, par value $.0001 per share; 1,000 shares authorized, 71 shares issued and outstanding, respectively

 
 
–
 
 
 
–
 

Convertible preferred stock Series C, par value $.0001 per share; 300 shares authorized, 290 shares issued and outstanding, respectively

 
 
–
 
 
 
–
 

Convertible preferred stock Series D, par value $.0001 per share; 5,000 shares authorized, 5,000 shares issued and outstanding, respectively

 
 
–
 
 
 
–
 

Convertible preferred stock Series E, par value $.0001 per share; 5,000 shares authorized, 5,000 shares issued and outstanding, respectively

 
 
 
 
 
 
–
 

Common stock, par value $.0001 per share; 150,000,000

 
 
–
 
 
 
–
 

shares authorized, 40,490,657 and 623,382 shares issued and outstanding, respectively

 
 
4
 
 
 
–
 

Additional paid-in capital

 
 
53,258
 
 
 
51,957
 

Accumulated deficit

 
 
(60,475
)
 
 
(60,680
)

Total stockholders' deficit

 
 
(7,213
)
 
 
(8,723
)

Total liabilities and stockholders' deficit

 
$
33
 
 
$
23
 

INSPYR THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF LOSSES
(unaudited)
(in thousands, except share and per share data)

 
Three Months Ended September 30,
 
 
Nine Months Ended
September 30,
 

 
2020
 
 
2019
 
 
2020
 
 
2019
 

Operating expenses:

Research and development

 
$
11
 
 
$
11
 
 
$
33
 
 
$
33
 

General and administrative

 
 
126
 
 
 
126
 
 
 
344
 
 
 
466
 

Total operating expenses

 
 
137
 
 
 
137
 
 
 
377
 
 
 
499
 

Loss from operations

 
 
(137
)
 
 
(137
)
 
 
(377
)
 
 
(499
)

Other income (expense):

Gain on change in fair value of derivative liability

 
 
2,024
 
 
 
959
 
 
 
353
 
 
 
640
 

Gain on conversion of debt

 
 
240
 
 
 
–
 
 
 
398
 
 
 
50
 

Interest expense, net

 
 
(21
)
 
 
(401
)
 
 
(169
)
 
 
(683
)

Income (loss) before provision for income taxes

 
 
2,106
 
 
 
421
 
 
 
205
 
 
 
(492
)

Provision for income taxes

 
 
–
 
 
 
–
 
 
 
–
 
 
 
–
 

Net income (loss)

 
$
2,106
 
 
$
421
 
 
$
205
 
 
$
(492
)

Net income (loss) per common share, basic

 
$
0.16
 
 
$
1.75
 
 
$
0.03
 
 
$
(2.08
)

Net income (loss) per common share, diluted

 
$
(0.00
)
 
$
(0.07
)
 
$
(0.00
)
 
$
(2.08
)

Weighted average shares outstanding, basic

 
 
13,344,461
 
 
 
240,000
 
 
 
6,818,722
 
 
 
237,070
 

Weighted average shares outstanding, diluted

 
 
542,003,815
 
 
 
2,047,302
 
 
 
535,478,076
 
 
 
237,070
 

About Inspyr Therapeutics, Inc.
Inspyr Therapeutics, Inc. is a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer. Our approach utilizes our proprietary delivery technology to better enhance immuno-modulation for improved therapeutic outcomes. Our potential first-in-class immune-oncology lead asset, RT-AR001, an adenosine receptor antagonist, is differentiated by its novel microparticle formulation that allows for better tumor infiltration and enhanced outcomes when administered intra-tumorally. Our patented portfolio of adenosine receptor antagonists provides flexibility to optimize treatment based on the specific targets found in each type of cancer.

Cautionary Statement Regarding Forward-Looking Information:
This news release contains "forward-looking statements" made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "seek" or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Inspyr Therapeutic's periodic reports filed with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Reports on Form 10-Q as well as and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.

CONTACT:

inspyrinfo@gmail.com

SOURCE: Inspyr Therapeutics, Inc.

ReleaseID: 618049

EVOTEC TO SUPPORT RAPPTA IN DEVELOPING SMALL MOLECULES THAT REACTIVATE PP2A, A KEY TUMOR SUPPRESSOR
THE COLLABORATION LEVERAGES EVOTEC'S ONCOLOGY EXPERTISE AND INTEGRATED DRUG DISCOVERY AND DEVELOPMENT PLATFORM

HAMBURG, GERMANY / ACCESSWIRE / November 24, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced a new multi-year drug development partnership with Rappta Therapeutics, a Finland-based biopharmaceutical company, focused on an innovative oncology target.

Under the partnership, Evotec will support Rappta's programme of developing small molecule activators of the enzyme Protein Phosphatase 2A ("PP2A"), which downregulates multiple oncogenic signalling pathways responsible for driving cancer progression. Although PP2A is a key tumour suppressor and has a critical function regulating protein de-phosphorylation and tumour growth, it has to-date been very difficult to target pharmaceutically.

Through its deep understanding of PP2A biology and the use of proprietary technology, Rappta has uniquely defined the PP2A target which has allowed them to come up with a series of first-in-class compounds which glue the three subunits of PP2A together, thus driving PP2A complex reformation and restoring its tumour suppressive function. Evotec and Rappta intend to develop the programme which is currently in the late lead optimisation stage towards IND-enabling studies over the course of their partnership.

The collaboration leverages Evotec's industry-leading integrated platform for drug discovery and development including Evotec's oncology expertise coupled with state-of-the-art technologies to maximise probability of success even in fields of cutting-edge and difficult science. Evotec receives undisclosed research funding and is eligible for success-based milestone payments.

Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: "Evotec is pleased to initiate this first collaboration with Rappta Therapeutics supporting their novel and next generation platform targeting PP2A against cancer. Evotec has a long and successful track record in the oncology field, having achieved numerous milestones including multiple pre-clinical candidates and clinical-stage assets together with our partners. We have been thoroughly impressed with the progress that Rappta has made in mapping out the PP2A target and look forward to working with them to continue their success by delivering solutions for patients with unmet medical needs."

Mikko Mannerkoski, the CEO of Rappta Therapeutics, added: "We are excited to be working on building a new platform and a novel class of pharmaceuticals to treat cancer. Rappta has a unique team whose deep understanding of PP2A biochemistry, structural biology, biogenesis, medicinal chemistry, and drug development is further supported by Evotec's capabilities. This is the perfect combination of expertise to translate these discoveries to the clinic."

ABOUT PROTEIN PHOSPHATASE 2A
Reversible phosphorylation is a fundamental mechanism controlling all cell signaling and communication and this process is regulated through the opposing actions of phosphatases (which remove phosphate groups from proteins) and kinases (which add phosphate groups to proteins). Altered cellular signaling as a result of protein hyperphosphorylation, results in the sustained growth of malignant cells and is a hallmark of human cancer development and progression. Protein Phosphatase 2A (PP2A) is a serine/threonine phosphatase that functions as a tumor suppressor by negatively regulating multiple oncogenic signaling pathways responsible for driving cancer progression. PP2A is made up of three subunits, that form a complete and active enzyme when bound together. The active enzyme is comprised of a scaffolding subunit (A), serving as the structural platform for the assembly of the catalytic (C) subunit and one substrate directing regulatory (B) subunit. In cancer, the tumor-suppressive activity of PP2A is often disrupted as a result of the inability of the three subunits to bind together correctly, rendering the PP2A enzyme inactive. This inactivation of PP2A, leads to increased oncogenic signaling, driving cancer progression and growth. Therefore, the reactivation of PP2A affords a unique therapeutic strategy to restore PP2A activity and cellular homeostasis, that can be used for the treatment of cancer and a broad range of other diseases.

ABOUT RAPPTA THERAPEUTICS
Rappta Therapeutics, a private biotech with operations in Finland and the US, is developing first-in-class anti-cancer drugs activating protein phosphatase 2A (PP2A). It has developed proprietary tools and a unique understanding of PP2A which allows it to therapeutically reactivate PP2A, a critical enzyme regulating protein de-phosphorylation and tumor growth, with the potential to create a new class of anti-cancer drugs. Rappta has a strong scientific, management and commercial team. Its scientific team represents world-leading expertise in PP2A. Rappta Therapeutics is backed by blue-chip investors Advent Life Sciences, Novartis Venture Fund, Novo Holdings and a family office. For more information, go to www.rappta-therapeutics.com.

ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.

FORWARD-LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com

SOURCE: Evotec AG via EQS Newswire

ReleaseID: 618169

NEW YORK, NY / ACCESSWIRE / November 24, 2020 / Madison Technologies Inc. (OTCQB:MDEX), a brand development and business accelerator company, is pleased to announce Posto Del Sole's inaugural jewelry launch: Brookland Jewelry. Located in Brooklyn and dedicated to giving back to its borough, Brookland Jewelry has created a collection of pendants and rings that reflect the Brooklyn motto, "In Unity There is Strength." The collection offers 14kt and sterling silver jewelry choices starting at $180.

Brooklyn, NY has an estimated population of 2.6 million with a very high population density of 36,732 people per square mile. With a rich history dating back over 350 years, immigrants continue to flock to this borough, making Brooklyn a great place to launch a borough themed jewelry brand.

Brookland Jewelry's holiday advertising and social media campaign will promote the "Unity Makes Strength" collection with 25% of the sales donated to the Brooklyn based Arthur Ashe Institute for Public Health.

"We keep the Brooklyn motto close to our hearts every day. We are thrilled to partner with the AAIUH in support of its vital mission and programs," says Jennifer Garfall, Chief Creative Officer at Posto Del Sole

Visit Brooklyn Jewelry's website, or follow them on Facebook, Instagram and Twitter.

About Madison Technologies Inc:
Madison Technologies is a brand development and business accelerator company. The company is focused on select consumer good segments that are deemed underserved and offer significant growth opportunities for our company.

About Posto Del Sole
Posto del Sole is a jewelry company focused on aggregating small designer brands via innovative and participatory digital channels. Led by former Tiffany & Co. executives, our team has the best design, product development, and sourcing expertise in the industry. This breadth and depth of experience is distinctly suited to helm a diverse portfolio of designer jewelry brands unified by their superb quality and craftsmanship. You can learn more at www.pdsbrands.com.

About Casa Zeta-Jones Brand
The CZJ product line will include a custom-designed handle and cartridge system, pre-care products, exclusive shaving products, and some of the best aftercare products on the market today. The Casa Zeta-Jones brand will transcend what is often considered a chore to a more pampering and lush women's shaving experience. You can learn more at www.czjlegs.com.

Forward-Looking Statements
Forward-looking statements and risks and uncertainties discussed in this press release may contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape, or manner of our future financial condition or stock price.

CONTACT:
Jeff Canouse, MDEX, CEO
jeff@madisontech.io

SOURCE: Madison Technologies, Inc.

ReleaseID: 618065

VANCOUVER, BC / ACCESSWIRE / November 24, 2020 / Noram Ventures Inc. ("Noram") (TSXV:NRM)(Frankfurt:N7R)(OTCQB:NRVTF) is pleased to announce that the Company has continued drilling in mineralization at depth on Hole #7 (CVZ-62).

Figure 1 – LF-70 drill rig on CVZ-62 site, 2020-11-17, Brad Peek, Senior Geologist and Q.P. on site, looking northwest. CVZ-62 has 50 meters of lithium claystone and is continuing to drill in the claystones. Samples have been submitted to ALS laboratories for analysis.

The Zeus property Esmeralda Formation playa lake bed sediments are horizontal and laterally continuous strata over kilometers and each drill intersection has a large radius of influence for resource estimates. This is evident in the February 20, 2019, Updated Inferred Lithium Mineral Resource Estimate, Zeus Project, Clayton Valley, Esmeralda County, Nevada, USA NI 43-101 technical report for the Zeus property, where the radius of influence is 250 meters or greater. "The prior hole CVZ-61, intersected approximately 298ft (91m) of lithium claystone. With a specific gravity of 1.74 g/cc for the claystone material, this corresponds to ~31 million tonnes that potentially can be added to the resources from this one intersection alone" commented Anita Algie, Director and CFO.

"CVZ-61 is to the east of a NE-SW possible fault, and it appears that the fault has not affected the claystone unit in a measurable way; i.e., there is no measurable displacement along the fault. This bodes well for the rest of the drilling to the east of the fault, which will cover an area approximately the same as the current resources (at >900 ppm lithium cutoff)" stated Brad Peek, consulting geologist and Qualified Person for this and all 4 of the previous drilling phases of Noram's Zeus Lithium property.

President and CEO, Dr. Tucker Barrie visited the Project this past week and reported:

"The Fall drill program is proceeding well. At present we have an LF-70 drill rig that can produce 50-60 feet of core per 12 hour shift. We are running one shift a day at present, but we will soon be going to 2 shifts with a Longyear 44 rig that is capable of 120+ feet per shift. We are on track to complete the drill program before Christmas.

On this visit I had the opportunity to meet with our neighbors in Clayton Valley who are producers of lithium and of other resources. There is potential for synergies in the production of these resources moving forward, and we will continue to have discussions in this regard. "

As well, I met with senior geologists from the Nevada Bureau of Mines and the United States Geological Survey to update them of our activities and to hear about their research related to lithium claystone deposits in Nevada. There are many ways we can work together, including providing access to our property and drill core for detailed mineralogical studies, and working toward possible lithium symposia in Nevada in the future. It would be ideal to gather industry, academia and the geological surveys to discuss Nevada's significant lithium resources and how to increase production for the growing electric vehicle market. "

The technical information contained in this news release has been reviewed and approved by Brad Peek., M.Sc., CPG, who is a Qualified Person with respect to Noram's Clayton Valley Lithium Project as defined under National Instrument 43-101.

About Noram Ventures Inc.

Noram Ventures Inc. (TSX – Venture: NRM / Frankfurt: N7R / OTCQB: NRVTF) is a Canadian based junior exploration company, with a goal of developing lithium deposits and becoming a low – cost supplier. The Company's primary business focus since formation has been the exploration of mineral projects. Noram's long term strategy is to build a multi-national lithium minerals company to produce and sell lithium into the markets of Europe, North America and Asia.

Please visit our web site for further information: www.noramventures.com

ON BEHALF OF THE BOARD OF DIRECTORS
/s/ "Anita Algie."
Director and CFO
Office: (604) 553-2279

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking information which is not comprised of historical facts. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release includes statements regarding, among other things, the completion transactions completed in the Agreement. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, regulatory approval processes. Although Noram believes that the assumptions used in preparing the forward-looking information in this news release are reasonable, including that all necessary regulatory approvals will be obtained in a timely manner, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Noram disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by applicable securities laws.

SOURCE: Noram Ventures Inc.

ReleaseID: 618026

TORONTO, ON / ACCESSWIRE / November 24, 2020 / Murchison Minerals Ltd. ("Murchison" or the "Company") (TSX-V:MUR)(OTC PINK:MURMF)  is pleased to announce the discovery of a new zinc, silver, gold and lead mineralization at Street Lake on the Brabant Lake project in Saskatchewan. The new mineralization consists of several grab samples collected 350 metres northwest of the northernmost tip of Street Lake during the 2020 summer prospecting program. The most significant sample was collected from a zone of extremely weathered outcrop (pictured below) where the rock has degraded almost entirely to rust coloured silt and sand, assayed 0.58% zinc, 0.17% lead and 32.4 g/t silver. The weathering was primarily affecting the mineralized zone and it is assumed that the oxidation of the sample may have significantly decreased the original zinc content of the primary rock.

Photo of Sample Location of 0.58% Zn, 0.17% Pb, 32.4 g/t Ag

Street Lake is located approximately 20 km northeast of the Brabant-McKenzie VMS Deposit. The area was staked based on a 2012 geophysical electromagnetic (EM) survey which highlighted a prospective conductor. A historic grab sample on the property collected by Great Bend Resources in 1987 assayed 1.19 g/t gold within a quartz vein. The 2020 prospecting work conducted by Murchison on the claim led to the discovery of this previously unknown zinc, lead, and silver mineralization.

The mineralization is located approximately 250 metres north-west of a series of EM conductors found along an 1,800 m long corridor observed in an airborne survey flown for First Graphite Corp. in 2012. The close proximity of the zinc, lead and silver mineralization to the EM conductors is encouraging and may indicate that the geophysical target is related to volcanogenic massive sulphide (VMS) mineralization similar to the Brabant-McKenzie Deposit. Limited historic diamond drilling by Hudson Bay Exploration and Development Company in 1977 on the far eastern extent of the conductive corridor intersected intervals of pyrite and graphite and included 3.05 metres of 0.1% zinc which is elevated well above background for the region. Follow-up prospecting is required to attempt to locate additional mineralization, and additional EM geophysical surveys are required to better locate the exact location of the historic EM conductors.

The area of deeply weathered zinc mineralization that was observed is approximately 4 m2 in size within an approximately 8 m2 outcrop. Sampling adjacent to the weathered zone in a rusty feldspar rich rock with disseminated galena and possible sericite alteration returned up to 0.38% lead and 18.1 g/t silver. An outcrop of rusty pegmatite was observed about 80 metres away and contained extensive quartz veining. Grab sampling of the pegmatite returned anomalous gold assays up to 0.38 g/t gold and 11.4 g/t silver.

Location Map of Street Lake 2020 Prospecting Results

Disseminated Fine Grained Galena Discovered Adjacent to Weathered Zinc Bearing Outcrop

Example of the Rusty Pegmatite with Anomalous Gold and Silver Assays Observed in Shallow Backpack Drill Hole

QA/QC

All rock samples were submitted to SRC Geoanalytical Laboratories in Saskatoon, Saskatchewan, Canada. They were analyzed twice using a partial and a total digest and ICP-OES. All samples were also analyzed for gold utilizing fire assay. SRC Geoanalytical Laboratories is an ISO certified and accredited laboratory.

Qualifying Statement

The foregoing scientific and technical disclosures have been reviewed by Andrew Masurat, P. Geo., and John Shmyr, P. Geo., qualified persons as defined by National Instrument 43-101. Mr. Masurat and Mr. Shmyr are independent consultants to Murchison and the Brabant-McKenzie project.

About the Brabant‐McKenzie VMS Project

The Brabant-McKenzie project is located 175 kilometres northeast of La Ronge, Saskatchewan and approximately three kilometres from the community of Brabant Lake. The area is accessed year-round via provincial Highway 102 and is serviced by grid power.

Brabant‐McKenzie VMS Deposit

The project consists of one mining lease, which hosts the Brabant-McKenzie VMS deposit, and additional mineral claims totalling 627 square kilometres, which cover approximately 57 kilometres of strike length over favourable geological horizons, multiple known mineralized showings and identified geophysical conductors.

About Murchison Minerals Ltd. (TSXV: MUR)

Murchison is a Canadian‐based exploration company focused on the exploration and development of the 100%-owned Brabant‐McKenzie zinc‐copper‐silver project in north‐central Saskatchewan. The Company also has a 100% interest in the HPM nickel‐copper‐cobalt project in Quebec. Murchison has 78.7 million shares issued and outstanding.

Additional information about Murchison and its exploration projects can be found on the Company's website at www.murchisonminerals.com. For further information, please contact:

Jean‐Charles (JC) Potvin, President and CEO
jcpotvin@murchisonminerals.com

Erik H Martin, CFO
Tel: (416) 350‐3776
info@murchisonminerals.com

Cathy Hume, CHF Capital Markets, CEO
Tel: 416-868-1079 x 231
cathy@chfir.com

Forward‐Looking Information

Certain information set forth in this news release may contain forward‐looking information that involves substantial known and unknown risks and uncertainties. This forward‐looking information is subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, the impact of general economic conditions, industry conditions, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward‐looking information. The parties undertake no obligation to update forward‐looking information except as otherwise may be required by applicable securities law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Murchison Minerals Ltd.

ReleaseID: 618033

DUBLIN, IRELAND / ACCESSWIRE / November 24, 2020 /

Key Highlights

Robust performance in a challenging trading environment
Further improvement in EBITDA and margin despite lower sales

Nine months ended 30 September

2020

LFL

Sales

$20.6bn

-3%

EBITDA

$3.4bn

2%

EBITDA Margin

16.60%

+100bps

Continued strong cash generation; expect year-end net debt/EBITDA of c. 1.4x
Non-cash impairment of c. $0.8bn expected in Q4
Agreement reached to divest of Brazil cement business for $0.2bn
Expect full-year EBITDA to be in excess of $4.4bn; ahead of 2019 on a LFL basis

Albert Manifold, Chief Executive, said today:

"As we continue to navigate these challenging times, the health and safety of our people remains our number one priority and is a core focus in our business each and every day. Markets continue to be impacted by the global pandemic and while we have seen some lower activity levels, I am pleased to report further improvement in trading performance, with an advance in both profitability and margins. The outlook for the coming months remains uncertain and visibility is limited, however, I am confident that we are well positioned for the challenges and opportunities that lie ahead."

Announced Tuesday, 24 November 2020

Health & Safety

As new waves of COVID-19 infections emerge across many of our markets, the health and safety of our people remains our number one priority. Our approach to workplace safety is uncompromising and our primary focus is to ensure that we provide a safe working environment for our employees, contractors and customers, enabling them to carry out their activities in accordance with the various health and safety protocols currently in place across our markets.

Trading Summary

Cumulative nine-month sales to the end of September amounted to $20.6 billion, a decrease of 3% compared with the corresponding period in 2019, maintaining the level of sales decline reported at the half year stage.

Third quarter trading in our Building Products Division was ahead, benefiting from strong residential repair, maintenance & improvement (RMI) demand in North America. While activity began to recover in Europe Materials in Q3, year-to-date sales remained behind prior year. In Americas Materials, Q3 sales performance was impacted by unfavourable weather conditions and a strong prior year comparative.

Sales (like-for-like1) change versus 2019

Americas Materials

Europe
Materials

Building
Products

Group

First half (H1)

-1%

-11%

+2%

-3%

Quarter 3 (Q3)

-7%

-2%

+4%

-3%

Nine months to September (9M)

-4%

-7%

+3%

-3%

Despite the lower sales, EBITDA for the period was $3.4 billion, up 1% on prior year and up 2% on a like-for-like basis reflecting a continued strong focus on cost rationalisation and mitigating actions to minimise the financial impacts of lower sales caused by the pandemic. The Group reported $65 million of non-recurring COVID-19 related restructuring items in the first six months of the year and we expect to incur similar costs in the second half.

EBITDA (like-for-like) change versus 2019

Americas
Materials

Europe
Materials

Building
Products

Group

First half (H1)

+20%

-28%

+11%

+2%

Quarter 3 (Q3)

+3%

+2%

+5%

+3%

Nine months to September (9M)

+9%

-14%

+9%

+2%

Trading Outlook

Based on the underlying trends in our businesses and recognising continued uncertainty across our markets, we expect full-year EBITDA to be in excess of $4.4 billion for 2020. For now, there is limited visibility into 2021, however the longer-term prospects for CRH remain positive, given our significant financial strength and operational resilience together with a portfolio of high-quality assets in attractive markets.

1 Like-for-like movements exclude the impact of currency exchange, acquisitions, divestments and non-recurring items.

Americas Materials

Nine-month like-for-like sales for our Americas Materials operations were 4% behind the equivalent period in 2019. Our North region was particularly impacted by COVID-19 restrictions earlier in the year while volumes in South were also impacted by delayed state lettings and unfavourable weather conditions. This was partly offset by healthy market fundamentals and solid backlogs in our West region along with pricing progress in most product lines. However, Q3 sales in the West region were impacted by unfavourable weather and wildfires in August and September. Our Cement business in North America experienced lower volumes in the first nine months of the year, however these were offset by pricing gains.

Like-for-like EBITDA for Q3 was ahead of 2019, resulting in nine-month EBITDA 9% ahead with solid price progression, good cost control and lower energy costs.

Key Products in Brief

Aggregates: Like-for-like aggregates volumes for the nine months were 3% behind 2019; average year-to-date prices increased by 3% with increases in all regions.
Asphalt: Delays in state lettings in the South region along with pandemic restrictions resulted in nine-month volumes 9% behind on a like-for-like basis; average prices were 2% behind impacted by lower bitumen input costs, however margins increased.
Readymixed Concrete: Volumes for the nine months were 5% behind 2019 on a like-for-like basis impacted by current year project delays along with the non-recurrence of large projects; average prices were 6% ahead.
Paving and Construction Services: Nine-month like-for-like sales in our paving and construction services business were 8% behind 2019 as solid activity in West was offset by pandemic restrictions and project delays in certain states.
Cement: COVID-19 restrictions, adverse weather conditions and lower demand from key sectors offset robust residential activity in western regions; nine-month like-for-like volumes were 1% behind 2019 while prices were 4% ahead with progress achieved in all markets.

Europe Materials

Nine-month like-for-like sales were 7% behind 2019, an improvement on the half year as trading activity recovered during Q3; however this was not sufficient to offset the impact of significant COVID-19 related government interventions and shutdowns in the second quarter. The United Kingdom (UK) which was one of the most significantly impacted markets saw some improvement in Q3 although activity levels are still below pre-COVID levels. Western European markets experienced improved activity levels in key markets as restrictions eased. Eastern European markets continued to trade well in Q3.

Like-for-like EBITDA for Q3 was ahead of prior year as improved pricing and the benefit of cost saving measures and lower energy costs offset the impact of lower volumes. Nine-month like-for-like EBITDA was 14% behind.

Key Markets in Brief

Western Europe: Despite some recovery in Q3 activity levels and continued pricing progress, nine-month sales were behind the prior year due to lower volumes which were impacted by strict COVID-19 restrictions in Q2, across a number of key markets such as the UK, Ireland and France. EBITDA was behind impacted by the lower sales, partly offset by cost rationalisation and improved cement pricing.
Eastern Europe: Nine-month sales were ahead of prior year as construction sites remained open throughout the pandemic. Higher cement volumes and improved pricing along with cost saving measures resulted in EBITDA ahead of the same period in 2019.
Asia: Despite record Q3 volumes, government shutdowns in the first half of the year resulted in lower nine-month volumes than prior year. Prices were also behind, impacted by product mix which resulted in lower sales compared to 2019. Lower energy costs along with operational and procurement initiatives resulted in EBITDA ahead for the nine months.

Building Products

Nine-month like-for-like sales were 3% ahead of 2019 reflecting strong volumes in Architectural Products, improved pricing in most platforms, benefits arising from commercial excellence, ongoing profit improvement and cost rationalisation initiatives. This resulted in strong operating leverage and like-for-like EBITDA for the nine months was 9% ahead of prior year.

Key Products in Brief

Architectural Products: Nine-month like-for-like sales and EBITDA were ahead of 2019 reflecting volume improvements in all key markets and product lines as well as selling price increases. In North America the significant increase in residential RMI demand experienced in the second quarter continued into Q3 while sales also remained robust in Europe, particularly in Germany and Poland. The businesses delivered strong operating leverage on the increased sales as price increases, disciplined cost control and the benefits of profit improvement initiatives were delivered.
Building Envelope: COVID-19 restrictions and "shelter in place" orders in key markets impacted volumes at both C.R. Laurence and our architectural glass operations, although the Q3 rate of decline softened with reduced restrictions. Nine-month like-for-like sales and EBITDA were behind 2019 as a result of lower volumes, partly offset by cost management initiatives to align costs with the lower activity levels.
Infrastructure Products: Nine-month like-for-like sales were behind prior year, driven by Q3 volume declines in North America due to slower demand in key product lines, COVID-19 restrictions in Europe earlier in the year and a downturn in the telecoms market in Australia. Despite the lower volumes, good pricing and stringent cost control resulted in nine-month like-for-like EBITDA ahead of 2019.
Construction Accessories: Nine-month like-for-like sales were behind the same period in 2019, mainly impacted by COVID-19 related business disruption in both Europe and North America. Some recovery has been experienced in recent months, particularly in Europe, while challenging market conditions continued to impact our businesses in North America. Like-for-like EBITDA was behind 2019, impacted by lower volumes and partly offset by cost reduction measures.

Profit Before Tax Outlook

We expect full-year depreciation and amortisation expense to be in line with last year (2019: $1.7 billion).

Arising from the Group's impairment testing process and as a result of the combined economic impacts of COVID-19 and Brexit, we expect to recognise non-cash impairment charges of c. $0.8 billion in our full-year results for 2020. These charges primarily relate to our UK business and our associate investment in China.

The net gain on divestments and non-current asset disposals in 2020 is expected to be c. $20 million (2019: $189 million loss).

The Group's share of profits from equity accounted entities (pre-impairment) is expected to be lower than prior year (2019: $67 million) mainly due to the divestment of the Indian joint venture along with the impact of COVID-19 restrictions on a number of operations.

Net finance costs are expected to be broadly in line with last year (2019: $490 million).

Taking each of these elements into account together with our EBITDA outlook, we expect full-year profit before tax (pre-impairment) to be ahead of 2019 (2019: $2.2 billion).

Balance Sheet Expectations

In line with our previous guidance, year-end net debt is expected to show a significant improvement on prior year (2019: $7.5 billion), to c. $6 billion resulting in net debt to EBITDA of approximately 1.4x based on robust EBITDA performance, continued strong working capital management, lower acquisition spend, lower capital expenditure in response to lower activity levels and a pause in the Group's share buyback programme.

Acquisitions and Divestments

The Group has spent c. $181 million on 14 acquisitions to date in 2020 (including deferred and contingent consideration in respect of prior year acquisitions).

On the divestment front, the Group completed seven transactions and realised total business and asset disposal proceeds of c. $263 million, inclusive of $122 million relating to the receipt of deferred proceeds from prior year divestments.

The agreement to divest our Brazil cement business for consideration of $0.2 billion is currently subject to competition authority review and the transaction is expected to close in 2021.

CRH will report its preliminary results for the full-year 2020 on Thursday, 4th March 2021.

CRH plc will host an analysts' conference call at 08:30 GMT on Tuesday, 24 November 2020 to discuss the Trading Update. To join this call please dial: +353 (0) 1 506 0650, confirmation code 1578116 (further international numbers are available here). A recording of the conference call will be available on the Results & Presentations page of the CRH website.

Contact CRH at +353 1 404 1000

Albert Manifold Chief ExecutiveSenan Murphy Finance Director

Frank Heisterkamp Director of Capital Markets & ESG

Tom Holmes Head of Investor Relations

About CRH

CRH (LSE:CRH)(ISE:CRG)(NYSE:CRH) is the leading building materials business in the world, employing c.79,000 people at c.3,100 operating locations in 30 countries. It is the largest building materials business in North America, a leading heavyside materials business in Europe and has positions in both Asia and South America. CRH manufactures and supplies a range of integrated building materials, products and innovative solutions which can be found throughout the built environment, from major public infrastructure projects to commercial buildings and residential structures. A Fortune 500 company, CRH is a constituent member of the FTSE 100 Index, the EURO STOXX 50 Index, the ISEQ 20 and the Dow Jones Sustainability Index (DJSI) Europe. CRH's American Depositary Shares are listed on the NYSE.

For more information visit www.crh.com

Disclaimer

In order to utilise the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, CRH public limited company (the "Company"), and its subsidiaries (collectively, "CRH" or the "Group") is providing the following cautionary statement.

This document contains statements that are or may be deemed to be forward-looking statements with respect to the financial condition, results of operations, business, viability and future performance of CRH and certain of the plans and objectives of CRH. These forward-looking statements may generally, but not always, be identified by the use of words such as "will", "anticipates", "should", "could", "would", "targets", "aims", "may", "continues", "expects", "is expected to", "estimates", "believes", "intends" or similar expressions. These forward-looking statements include all matters that are not historical facts or matters of fact at the date of this document.

By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that may or may not occur in the future and reflect the Company's current expectations and assumptions as to such future events and circumstances that may not prove accurate.

A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, certain of which are beyond our control, as detailed in the section entitled "Risk Factors" in our 2019 Annual Report on Form 20-F as filed with the US Securities and Exchange Commission.

You are cautioned not to place undue reliance on any forward-looking statements. These forward-looking statements are made as of the date of this document. The Company expressly disclaims any obligation or undertaking to publicly update or revise these forward-looking statements other than as required by applicable law.

The forward-looking statements in this document do not constitute reports or statements published in compliance with any of Regulations 6 to 8 of the Transparency (Directive 2004/109/EC) Regulations 2007.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: CRH PLC

ReleaseID: 618085

VANCOUVER, BC / ACCESSWIRE / November 24, 2020 / FIORE GOLD LTD. (TSXV:F)(OTCQB:FIOGF)(FRA:2FO) ("Fiore" or the "Company") is pleased to report results from the current drilling program at its Gold Rock project in Nevada (Figure 1). These latest results continue to demonstrate thick intervals of oxide gold mineralization both within and outside of the current resource pit shells. We view this as encouraging in our efforts to upgrade Inferred resources and expand the overall resource envelope as part of the ongoing Feasibility Study ("FS") at Gold Rock.

Highlights from the sixty-two holes reported here include:

48.8 m of 2.17 g/t gold in hole GR20-009
16.8 m of 1.12 g/t gold in hole GR20-021
41.2 m of 0.97 g/t gold in hole GR20-027
19.8 m of 1.10 g/t gold in hole GR20-029
33.5 m of 0.89 g/t gold in hole GR20-036
19.8 m of 1.38 g/t gold in hole GR20-038
32.0 m of 1.41 g/t gold in hole GR20-049
18.3 m of 1.16 g/t gold in hole GR20-051
18.3 m of 1.19 g/t gold in hole GR20-065
38.1 m of 1.11 g/t gold in hole GR20-068

In the southern part of the deposit, cross-section 1 (Figure 2) shows one of the best Gold Rock intercepts to date in hole GR20-009, which intercepted 48.8 metres of 2.17 g/t gold just below the base of the current southern pit shell from the 2020 Preliminary Economic Assessment ("PEA"). Two other very strong intercepts, 32.0 metres of 1.41 g/t gold in hole GR20-049 and 38.1 metres of 1.11 g/t gold in hole GR20-068 were also located in the southern part of the deposit.

Cross-section 2 (Figure 3) is in the gap between the current PEA pit shells and shows stronger mineralization in the eastern limb of the Easy Junior anticline. Hole GR20-010 intercepted 10.7 metres of 0.73 g/t gold and demonstrates that mineralization remains open to the east. The goal of drilling in this area was to see if sufficient mineralization could be defined to pull the two PEA pit shells together into a single pit, and these results are encouraging in that regard, particularly if mineralization continues to be encountered along the eastern side of the anticline.

Cross-section 3 (Figure 4) runs through the former EZ Junior heap leach pad area where several holes have delineated mineralization below (GR20-029 and GR20-036) and to the east (GR20-028 and GR20-025) of the current PEA pit shell. Interestingly, the holes drilled through the former leach pad also show significant residual gold remaining in the leach pad material (e.g. holes GR20-029 with 15.2 metres of 0.32 g/t gold).

Cross-section 4 (Figure 5) again shows multiple intercepts below the current PEA pit shells in both the west and east limbs of the EZ anticline structure. Hole GR20-027 intercepted 41.2 metres of 0.97 g/t gold and 25.9 metres of 0.31 g/t, while GR20-038 encountered 6.1 metres of 0.45 g/t gold immediately followed by 19.8 metres of 1.38 g/t gold.

Tim Warman, Fiore's CEO stated, "These holes represent the first of the RC holes from the 2020 drilling program at Gold Rock, with the results continuing to show strong, consistent mineralization and excellent opportunities to expand the current resource envelope going into the Feasibility Study. Work on the FS is progressing well with the large diameter metallurgical core holes completed and in the process of being logged before being delivered to the metallurgical lab for further testing. The first round of HQ core holes has also been completed, including detailed geotechnical logging, with geological logging and sampling underway. Several exploration holes have also been drilled at the Jasperoid Creek target approximately 1.05 miles (1.7 km) north of the former Easy Junior pit (Figure 1).

We have been seeing longer than normal wait times for assays as the labs deal with COVID-19 protocols, so we plan to take a short break from drilling at Gold Rock to allow the assay lab to catch up, with several of the drills moving over to the Pan Mine in the interim. Drilling completed to date as part of the current program at Gold Rock includes approximately 105 RC holes, 20 HQ core holes, and 15 PQ metallurgical core holes. With all this activity it's going to be a busy and exciting year ahead for Fiore and we're looking forward to progressing the Gold Rock FS and providing the first detailed view of our next mine."

Complete results for the sixty-two holes referenced in this press release are shown in the table below. Note that holes GR20-017, -032, -041, -043 and -057 were drilled as pre-collars for HQ and metallurgical PQ core holes, and the assay results for the HQ and PQ core portions of these holes are still pending.

Hole

From

(m)

To

(m)

Length

(m)

Grade

(g/t Au)

GR20-001

117.35

123.44

6.10

0.96

includes

118.87

121.92

3.05

1.23

GR20-002

no significant results

GR20-003

100.58

106.68

6.10

1.02

includes

100.58

103.63

3.05

1.62

and

124.97

140.21

15.24

0.54

GR20-004

179.83

185.93

6.10

0.36

GR20-005

109.73

115.82

6.10

0.28

and

120.40

140.21

19.81

0.69

includes

129.54

132.59

3.05

2.37

GR20-006

no significant results

GR20-007

140.21

144.78

4.57

1.26

includes

141.73

144.78

3.05

1.40

GR20-008

135.64

141.73

6.10

0.25

GR20-009

155.45

160.02

4.57

0.27

and

166.12

214.88

48.77

2.17

GR20-010

108.20

111.25

3.05

0.35

and

118.87

129.54

10.67

0.73

includes

121.92

124.97

3.05

1.20

and

220.98

228.60

7.62

1.04

includes

224.03

227.08

3.05

1.94

GR20-011

no significant results

GR20-012

108.20

126.49

18.29

0.47

and

169.16

172.21

3.05

0.88

GR20-013

no significant results

GR20-014

92.96

103.63

10.67

0.39

GR20-015

no significant results

GR20-016

45.72

51.82

6.10

0.25

GR20-017

RC pre-collar for core hole

GR20-018

172.21

184.40

12.19

0.39

and

193.55

196.60

3.05

0.24

GR20-019

237.74

257.56

19.81

0.47

GR20-020

131.06

135.64

4.57

0.28

GR20-021

126.49

129.54

3.05

0.56

and

134.11

150.88

16.76

1.23

includes

140.21

144.78

4.57

2.59

and

156.97

170.69

13.72

0.73

GR20-022

no significant results

GR20-023

no significant results

GR20-024

no significant results

GR20-025

1.52

10.67

9.14

0.21

and

112.78

121.92

9.14

0.43

and

128.02

143.26

15.24

0.57

GR20-026

no significant results

GR20-027

21.34

30.48

9.14

0.43

and

149.35

190.50

41.15

0.97

includes

153.92

185.93

32.00

1.14

and

195.07

220.98

25.91

0.31

GR20-028

0.00

12.19

12.19

0.27

and

97.54

117.35

19.81

0.58

and

123.44

132.59

9.14

1.37

includes

124.97

132.59

7.62

1.50

GR20-029

0.00

15.24

15.24

0.32

and

19.81

22.86

3.05

0.60

and

164.59

184.40

19.81

1.10

includes

169.16

179.83

10.67

1.64

GR20-030

158.50

166.12

7.62

0.83

GR20-031

38.10

41.15

3.05

0.25

and

131.06

134.11

3.05

0.36

and

140.21

169.16

28.96

0.61

and

173.74

176.78

3.05

0.38

and

182.88

185.93

3.05

0.25

GR20-032

RC pre-collar for core hole

GR20-033

109.73

131.06

21.34

0.89

includes

118.87

126.49

7.62

1.51

GR20-034

no significant results

GR20-035

no significant results

GR20-036

97.54

131.06

33.53

0.89

includes

97.54

112.78

15.24

1.57

and

170.69

182.88

12.19

0.42

and

187.45

190.50

3.05

0.57

GR20-037

no significant results

GR20-038

166.12

172.21

6.10

0.45

GR20-038

176.78

196.60

19.81

1.38

includes

187.45

193.55

6.10

3.25

GR20-039

no significant results

GR20-040

135.64

141.73

6.10

1.01

includes

135.64

138.68

3.05

1.52

GR20-041

RC pre-collar for core hole

GR20-042

108.20

111.25

3.05

0.38

GR20-042

158.50

164.59

6.10

0.49

GR20-043

RC pre-collar for core hole

GR20-044

no significant results

GR20-045

no significant results

GR20-046

0.00

4.57

4.57

0.21

GR20-047

no significant results

GR20-048

115.82

120.40

4.57

0.34

GR20-048

128.02

144.78

16.76

0.51

GR20-049

108.20

140.21

32.00

1.41

includes

109.73

123.44

13.72

2.46

GR20-050

181.36

188.98

7.62

0.34

GR20-051

132.59

150.88

18.29

1.16

includes

134.11

150.88

16.76

1.23

GR20-052

no significant results

GR20-053

no significant results

GR20-054

no significant results

GR20-055

129.54

132.59

3.05

0.35

GR20-055

137.16

150.88

13.72

1.27

includes

141.73

146.30

4.57

2.68

GR20-055

275.84

286.51

10.67

0.29

GR20-056

no significant results

GR20-057

RC pre-collar for core hole

GR20-058

no significant results

GR20-059

121.92

128.02

6.10

0.53

GR20-060

80.77

94.49

13.72

0.32

GR20-060

106.68

117.35

10.67

0.68

GR20-061

0.00

19.81

19.81

0.26

GR20-061

160.02

182.88

22.86

0.72

includes

169.16

173.74

4.57

2.33

GR20-062

181.36

187.45

6.10

0.30

GR20-063

no significant results

GR20-064

143.26

149.35

6.10

0.32

GR20-065

108.20

126.49

18.29

1.19

includes

111.25

123.44

12.19

1.51

GR20-066

assays pending

GR20-067

assays pending

GR20-068

47.24

56.39

9.14

0.70

GR20-068

60.96

99.06

38.10

1.11

includes

83.82

97.54

13.72

2.33

GR20-069

assays pending

GR20-070

1.52

12.19

10.67

0.38

Assay highlights are calculated with a cutoff of 0.006 opt (0.20 g/t) Au. Highlighted intervals contain less than 10 feet (3 m) of material below cutoff grade.

The holes in this release are all reverse circulation ("RC") holes and represent an initial 45,000 feet (13,700 m) of a drilling program consisting of a mix of HQ and PQ diamond core holes as well as RC and sonic holes. Total planned footage for the drilling program to support the FS will be approximately 198,000 ft (60,000 m), with approximately 115,000 ft (35,000 m) focused on resource expansion to add Measured and Indicated resources for inclusion in the FS.

Gold Rock Project and PEA Highlights

The federally permitted Gold Rock gold project ("Gold Rock", or the "Project") is located approximately 8 miles southeast of the Pan Mine in White Pine County, Nevada. The recently released Gold Rock Preliminary Economic Assessment ("PEA") provides an updated mineral resource estimate and a base case assessment of developing the Project as a satellite open pit operation that will share significant infrastructure and management with the adjacent Pan Mine. The PEA also identifies a considerable number of opportunities to enhance the project economics as Gold Rock advances to the Feasibility stage by drilling to increase the mineral resource, further metallurgical testing aimed at optimizing recoveries, and geotechnical drilling aimed at reducing the stripping ratio. Further updates will be provided as we progress work in these areas. The PEA was prepared in accordance with Canadian Securities Administrators' National Instrument 43-101 Standards of Disclosure for Mineral Projects ("NI 43-101"). A Technical Report with the details of the PEA is available on SEDAR under the Company's profile.

Gold Rock Mineral Resource Estimate

The Company's updated Mineral Resource Estimate ("MRE"; effective date of March 31, 2020) was completed by APEX and forms the basis for the PEA. A summary of the MRE is highlighted in the table below.

Pit-Constrained Mineral Resource Summary

Resource Classification

Cut-off opt/gpt

Tons/Tonnes

Gold opt/gpt

Gold Ounces

Total Indicated

0.003/0.09

20.9/19.0

0.019/0.66

403,000

Total Inferred

0.003/0.09

3.0 /2.7

0.025/0.87

84,300

Key Assumptions, Parameters, and Methods related to the Mineral Resource Estimates:

Mineral Resources were prepared in accordance with NI 43-101 and the CIM Definition Standards (2014). Mineral Resources that are not mineral reserves do not have demonstrated economic viability.
Troy ounces per short ton ("opt") / grams per tonne ("gpt")
This estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, taxation, sociopolitical, marketing, or other relevant issues.
Open pit Mineral Resources are reported at a cut-off grade of 0.003 opt/0.09 gpt gold that is based on a gold price of US$1,500/oz. A revenue price of US$1,400 is used for the base case economic model.
The Mineral Resources are constrained by a pit shell with appropriate mining costs, processing costs, metal recoveries, and pit slope angles.
Rounding may result in apparent summation differences between tonnes, grade, and contained metal content.
Contained gold ounces are in troy ounces.

Technical Report & Qualified Persons

The scientific and technical information relating to Fiore Gold's properties contained in this news release was approved by Paul Noland (AIPG CPG-11293), Fiore Gold's VP Exploration and a "Qualified Person" under National Instrument 43-101. References to the Gold Rock project PEA are taken from the "Technical Report on the Preliminary Economic Assessment of the Gold Rock Project, White Pine County, Nevada, USA" (the "Technical Report"). The Technical Report, which is dated April 30, 2020 with an effective date of March 31, 2020, was prepared in compliance with National Instrument 43-101 – Standards for Disclosure for Mineral Projects ("NI 43-101") and is available under Fiore's profile on SEDAR at www.sedar.com and on the Company's website at fioregold.com. The report is authored by Michael B. Dufresne, , M.Sc., P.Geol., P.Geo., Gregory B, Sparks, B.Sc., P.Eng., Sam J. Shoemaker, Jr., B.S., SME Registered Member, Warren E. Black, M.Sc., P.Geo., and Steven J. Nicholls, BA.Sc., MAIG.

Corporate Strategy

Our corporate strategy is to grow Fiore into a 150,000 ounce per year gold producer. To achieve this, we intend to:

grow gold production at the Pan Mine while also growing the reserve and resource base;
advance exploration and development of the nearby Gold Rock project; and
acquire additional production or near-production assets to complement our existing operations

On behalf of FIORE GOLD LTD.

"Tim Warman"

Chief Executive Officer

Contact Us:

info@fioregold.com

1 (416) 639-1426 Ext. 1
www.fioregold.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward Looking Statements

This news release contains "forward-looking statements" and "forward looking information" (as defined under applicable securities laws), based on management's best estimates, assumptions and current expectations. Such statements include but are not limited to, statements with respect to any future mining operations at Gold Rock, including those described in the PEA, the resource expansion and drilling program, potential to upgrade inferred resources and expanding the overall resource envelope at the Gold Rock project, plans for and progress toward a Gold Rock Feasibility Study, anticipated results of drilling and studies, mineral resource estimates expectations that the Company will add additional mineral resources, improving and optimizing mineral recoveries at Gold Rock, future gold production, company outlook, goal to become a 150,000 ounce producer, goal to acquire additional production or near production assets, and other statements, estimates or expectations. Often, but not always, these forward-looking statements can be identified by the use of forward-looking terminology such as "expects", "expected", "budgeted", "targets", "forecasts", "intends", "anticipates", "scheduled", "estimates", "aims", "will", "believes", "projects" and similar expressions (including negative variations) which by their nature refer to future events. By their very nature, forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Fiore Gold's control. These statements should not be read as guarantees of future performance or results. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, as well as a number of assumptions made by, and information currently available to, the Company concerning, among other things, anticipated geological formations, potential mineralization, future plans for exploration and/or development, potential future production, ability to obtain permits for future operations, drilling exposure, and exploration budgets and timing of expenditures, all of which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement of Fiore Gold to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to vary materially from results anticipated by such forward looking statements include, but not limited to, risks related to the Pan Mine performance, risks related to the COVID-19 pandemic, including government restrictions impacting the Company's operations, risks the pandemic poses to its work-force, impacts the virus may have on ability to obtain services and materials from its suppliers and contractors; risks related to the company's limited operating history; risks related to international operations; risks related to general economic conditions, actual results of current or future exploration activities, unanticipated reclamation expenses; changes in project parameters as plans continue to be refined; fluctuations in prices of metals including gold; fluctuations in foreign currency exchange rates; increases in market prices of mining consumables; possible variations in ore reserves, grade or recovery rates; uncertainties involved in the interpretation of drilling results, test results and the estimation of gold resources and reserves; failure of plant, equipment or processes to operate as anticipated; the possibility that capital and operating costs may be higher than currently estimated; the possibility of cost overruns or unanticipated expenses in the work programs; availability of financing; accidents, labour disputes, title disputes, claims and limitations on insurance coverage and other risks of the mining industry; delays in the completion of exploration, development or construction activities; the possibility that required permits may not be obtained on a timely manner or at all; changes in national and local government regulation of mining operations, tax rules and regulations, and political and economic developments in countries in which Fiore Gold operates, and other factors identified in Fiore Gold's filings with Canadian securities authorities under its profile at www.sedar.com respecting the risks affecting Fiore and its business. Although Fiore has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The forward-looking statements and forward-looking information are made as of the date hereof and are qualified in their entirety by this cautionary statement. Fiore disclaims any obligation to revise or update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results, events or developments, except as require by law. Accordingly, readers should not place undue reliance on forward-looking statements and information.

SOURCE: Fiore Gold Ltd.

ReleaseID: 618074